Jan 23 (Reuters) - Ascentage Pharma 6855.HK said on Thursday it aims to raise $126.4 million in an initial public offering in the U.S., becoming the first sizeable Chinese firm to seek a listing in the United States this year.
(Reporting by Gursimran Kaur in Bengaluru; Editing by Subhranshu Sahu)
((GursimranKaur.Mehar@thomsonreuters.com, https://x.com/GursimranKMehar;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.